| Literature DB >> 31090382 |
Zh M Sizova1, E V Shikh1, A A Makhova1.
Abstract
The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases. Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists. Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4. When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine. Keywords: L-carnitine, P450 CYP 3А4, chronic heart failure, myocardial infarction, chronic renal failure, inter-drug interaction, antioxidant, antihypoxant.Entities:
Keywords: L-carnitine; P450 CYP 3А4; antihypoxant; antioxidant; chronic heart failure; chronic renal failure; inter-drug interaction; myocardial infarction
Mesh:
Substances:
Year: 2019 PMID: 31090382 DOI: 10.26442/00403660.2019.01.000040
Source DB: PubMed Journal: Ter Arkh ISSN: 0040-3660 Impact factor: 0.467